Table 1.

Baseline characteristics of study participants

Patients (n)153
Age (yr)63.0±13.4
Men/women (n/n)89/64
Body weight (kg)73.4±14.8
Height (m)1.67±0.1
Body mass index (kg/m2)26.6±7.7
Dialysis vintage (mo)27 (12, 53)
Presence of diabetes, n (%)51 (33.3)
Presence of hypertension, n (%)122 (79.7)
Presence of dyslipidemia, n (%)41 (26.8)
Current smokers, n (%)34 (22.2)
History of coronary heart disease, n (%)35 (22.9)
History of cerebrovascular disease, n (%)14 (9.2)
Hematocrit (%)35.0±3.8
Hemoglobin (g/dl)11.3±1.3
Serum urea (mg/dl)138.0±36.0
Serum creatinine (mg/dl)8.2±0.5
Serum calcium (mg/dl)8.9±0.7
Serum phosphate (mg/dl)5.1±1.5
Parathyroid hormone (ng/L)292.0±21.6
Total protein (g/dl)7.5±0.6
Serum albumin (g/dl)4.0±0.4
Total cholesterol (mg/dl)159.4±45.6
LDL cholesterol (mg/dl)78.5±30.8
HDL cholesterol (mg/dl)48.4±25.6
Triglycerides (mg/dl)165.6±48.6
Use of antihypertensive drugs, n (%)117 (76.4)
 Renin inhibitors1 (0.7)
 ACE inhibitors 9 (5.9)
 ARBs31 (20.3)
 CCBs73 (47.7)
 Central-acting agents28 (18.3)
β-blockers81 (52.9)
No. of antihypertensive drugs2 (1, 3)
Nitrates, n (%)20 (13.1)
Loop diuretics, n (%)55 (35.9)
Statins, n (%)65 (42.4)
  • Data are presented as mean±SD or absolute and relevant frequencies with the exceptions of dialysis vintage and number of antihypertensive drugs, which are expressed as median (25th, 75th percentile). ACE, angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers; CCBs, calcium channel blockers.